STOCK TITAN

bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
bluebird bio, Inc. (BLUE) will host a conference call on March 26, 2024, to discuss Q4 and 2023 annual results and business updates. The call can be accessed via telephone or webcast.
Positive
  • None.
Negative
  • None.

SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss fourth quarter and 2023 annual results and business updates on March 26, 2024, at 8:00 a.m. ET.

To access the live conference call via telephone, please register at this link to receive a dial in number and unique PIN.

The live webcast of the call may be accessed by visiting the “Events & Presentations” page within the Investors & Media section of the bluebird website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird website for 90 days following the event.

About bluebird bio, Inc.

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for three therapies in under two years. Today, we are proving and scaling the commercial model for gene therapy and delivering innovative solutions for access to patients, providers, and payers.

With a dedicated focus on severe genetic diseases, bluebird has the largest and deepest ex-vivo gene therapy data set in the field, with industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

bluebird continues to forge new paths as a standalone commercial gene therapy company, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

Investors:

Courtney O’Leary, 978-621-7347

coleary@bluebirdbio.com

Media:

Jess Rowlands, 857-299-6103

jess.rowlands@bluebirdbio.com

Source: bluebird bio, Inc.

FAQ

When will bluebird bio host the conference call?

bluebird bio will host the conference call on March 26, 2024.

What will the conference call discuss?

The call will discuss fourth quarter and 2023 annual results and business updates.

How can I access the conference call?

You can access the call via telephone by registering at the provided link or through the webcast on the bluebird website.

Where can I find the webcast replay?

The webcast replay will be available on the bluebird website for 90 days after the event.

bluebird bio, Inc.

NASDAQ:BLUE

BLUE Rankings

BLUE Latest News

BLUE Stock Data

80.75M
193.91M
0.63%
43.76%
25.48%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SOMERVILLE